Toll Free: 1-888-928-9744

Synthon Holdings BV - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Synthon Holdings BV - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Synthon Holdings BV - Product Pipeline Review - 2015', provides an overview of the Synthon Holdings BV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Synthon Holdings BV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Synthon Holdings BV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Synthon Holdings BV's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Synthon Holdings BV's pipeline products

Reasons To Buy

- Evaluate Synthon Holdings BV's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Synthon Holdings BV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Synthon Holdings BV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Synthon Holdings BV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Synthon Holdings BV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Synthon Holdings BV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Synthon Holdings BV Snapshot 5 Synthon Holdings BV Overview 5 Key Information 5 Key Facts 5 Synthon Holdings BV - Research and Development Overview 6 Key Therapeutic Areas 6 Synthon Holdings BV - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Out-Licensed Products 10 Out-Licensed Products/Combination Treatment Modalities 11 Synthon Holdings BV - Pipeline Products Glance 12 Synthon Holdings BV - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Synthon Holdings BV - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Synthon Holdings BV - Drug Profiles 15 SYD-985 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Monoclonal Antibody Conjugated 2 for Cancer 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Dendritic Cell Therapy for Cancer 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Monoclonal Antibody Conjugated 3 for Cancer 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibody Conjugated 4 for Cancer 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibody for Cancer 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecules for Multiple Sclerosis 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Synthon Holdings BV - Pipeline Analysis 23 Synthon Holdings BV - Pipeline Products by Target 23 Synthon Holdings BV - Pipeline Products by Route of Administration 24 Synthon Holdings BV - Pipeline Products by Molecule Type 25 Synthon Holdings BV - Pipeline Products by Mechanism of Action 26 Synthon Holdings BV - Recent Pipeline Updates 27 Synthon Holdings BV - Dormant Projects 28 Synthon Holdings BV - Company Statement 29 Synthon Holdings BV - Locations And Subsidiaries 30 Head Office 30 Other Locations & Subsidiaries 30 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Synthon Holdings BV, Key Information 5 Synthon Holdings BV, Key Facts 5 Synthon Holdings BV - Pipeline by Indication, 2015 7 Synthon Holdings BV - Pipeline by Stage of Development, 2015 8 Synthon Holdings BV - Monotherapy Products in Pipeline, 2015 9 Synthon Holdings BV - Out-Licensed Products in Pipeline, 2015 10 Synthon Holdings BV - Out-Licensed Products/ Combination Treatment Modalities, 2015 11 Synthon Holdings BV - Phase I, 2015 12 Synthon Holdings BV - Preclinical, 2015 13 Synthon Holdings BV - Discovery, 2015 14 Synthon Holdings BV - Pipeline by Target, 2015 23 Synthon Holdings BV - Pipeline by Route of Administration, 2015 24 Synthon Holdings BV - Pipeline by Molecule Type, 2015 25 Synthon Holdings BV - Pipeline Products by Mechanism of Action, 2015 26 Synthon Holdings BV - Recent Pipeline Updates, 2015 27 Synthon Holdings BV - Dormant Developmental Projects,2015 28 Synthon Holdings BV, Subsidiaries 30



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify